Prestige Consumer Healthcare, Inc. (PBH) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1159347,
    "name": "Prestige Consumer Healthcare, Inc.",
    "stock_name": "Prestige Consumer Healthcare, Inc.",
    "full_name": "Prestige Consumer Healthcare, Inc.",
    "name_url": "stocks-analysis/prestige-consumer-healthcare-inc",
    "exchange": 207,
    "exchangecode": "NYS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "60.06",
    "chg": -0.22,
    "chgp": "-0.36%",
    "dir": -1,
    "prev_price": "60.28",
    "mcapval": "3,510.89",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US74112D1019",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "256.81 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/prestige-consumer-healthcare-inc-1159347-207&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Prestige Consumer Healthcare, Inc. Experiences Revision in Its Stock Evaluation Amid Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/prestige-consumer-healthcares-valuation-grade-downgraded-from-attractive-to-fair-3686249",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/PrestigeConsume_valuationdot_3686249.png",
        "date": "2025-11-10 15:55:39",
        "description": "Prestige Consumer Healthcare, Inc. has adjusted its valuation amid shifts in financial metrics and market standing within the Pharmaceuticals & Biotechnology sector. The company displays various profitability ratios and has faced performance challenges this year, contrasting with the broader market and highlighting the competitive landscape and differing risk profiles among peers."
      },
      {
        "title": "Prestige Consumer Healthcare Stock Hits New 52-Week Low at $59.62",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/prestige-consumer-healthcare-stock-hits-new-52-week-low-at-5962-3667279",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/PrestigeConsume_priceRelatedfactors_3667279.png",
        "date": "2025-11-03 17:06:31",
        "description": "Prestige Consumer Healthcare, Inc. has reached a new 52-week low, trading at USD 59.62 as of October 31, 2025. The company has seen a 7.75% decline over the past year, contrasting with the S&P 500's performance. Financial metrics show mixed results, with high institutional ownership and recent low quarterly sales figures."
      },
      {
        "title": "Prestige Consumer Healthcare, Inc. Experiences Revision in Its Stock Evaluation Amid Competitive Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/prestige-consumer-healthcares-valuation-grade-downgraded-from-very-attractive-to-attractive-3667095",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/PrestigeConsume_valuationdot_3667095.png",
        "date": "2025-11-03 15:53:10",
        "description": "Prestige Consumer Healthcare, Inc. has adjusted its valuation, showcasing a P/E ratio of 20 and a price-to-book value of 2.48. The company demonstrates solid profitability with a ROCE of 12.76% and ROE of 12.16%, positioning it competitively within the pharmaceuticals and biotechnology sector."
      },
      {
        "title": "Prestige Consumer Healthcare, Inc. Experiences Revision in Its Stock Evaluation Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/prestige-consumer-healthcares-valuation-grade-downgraded-from-very-attractive-to-attractive-3649070",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/PrestigeConsume_valuationdot_3649070.png",
        "date": "2025-10-27 15:53:58",
        "description": "Prestige Consumer Healthcare, Inc. has adjusted its valuation within the pharmaceuticals and biotechnology sector, with key metrics indicating operational efficiency and profitability. The company's performance has fluctuated, showing a decline over the past year compared to the broader market, highlighting challenges in the current environment."
      },
      {
        "title": "Is Prestige Consumer Healthcare, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-prestige-consumer-healthcare-inc-overvalued-or-undervalued-3637705",
        "imagepath": "",
        "date": "2025-10-21 12:07:26",
        "description": "As of 17 October 2025, the valuation grade for Prestige Consumer Healthcare, Inc. has moved from very attractive to attractive, indicating a shift towards a more cautious outlook. The company appears to be overvalued based on its current metrics, with a P/E ratio of 20, a Price to Book Value of 2.48, and an EV to EBITDA ratio of 14.39, all of which are higher than those of its peers. For instance, Alkermes Plc has a P/E of 13.77 and an EV to EBITDA of 9.41, suggesting that Prestige is trading at a premium compared to its industry counterparts.\n\nThe company's recent performance shows a stark contrast to the broader market, with a year-to-date return of -20.49% compared to the S&P 500's gain of 13.30%. This underperformance, along with the high valuation ratios, reinforces the conclusion that Prestige Consumer Healthcare, Inc. is currently overvalued...."
      },
      {
        "title": "Is Prestige Consumer Healthcare, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-prestige-consumer-healthcare-inc-overvalued-or-undervalued-3634575",
        "imagepath": "",
        "date": "2025-10-20 12:24:50",
        "description": "As of 17 October 2025, the valuation grade for Prestige Consumer Healthcare, Inc. has moved from very attractive to attractive, indicating a slight decline in perceived value. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 20, which is higher than the peer average of approximately 15.85, and a PEG ratio of 3.01, suggesting that the stock is expensive relative to its growth prospects. Additionally, the EV to EBITDA ratio stands at 14.39, which is also above the peer average of 11.55.\n\nIn comparison to its peers, Alkermes Plc has a P/E ratio of 13.77 and an EV to EBITDA of 9.41, while ACADIA Pharmaceuticals, Inc. shows a higher P/E ratio of 19.28 but a significantly high EV to EBITDA of 33.99. This highlights that Prestige Consumer Healthcare is trading at a premium compared to some of its peers. Furthermore, the company's stock has underperformed relative ..."
      },
      {
        "title": "Is Prestige Consumer Healthcare, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-prestige-consumer-healthcare-inc-overvalued-or-undervalued-3632109",
        "imagepath": "",
        "date": "2025-10-19 12:02:24",
        "description": "As of 17 October 2025, the valuation grade for Prestige Consumer Healthcare, Inc. moved from very attractive to attractive, indicating a shift in perceived value. The company appears overvalued based on its current metrics, with a P/E ratio of 20, a Price to Book Value of 2.48, and an EV to EBITDA of 14.39. In comparison, peers such as Alkermes Plc have a P/E of 13.77 and an EV to EBITDA of 9.41, suggesting that Prestige is trading at a premium relative to its industry.\n\nThe stock has underperformed against the S&P 500 over various periods, notably with a year-to-date return of -20.49% compared to the index's 13.30%. This underperformance, alongside the elevated valuation ratios, reinforces the conclusion that Prestige Consumer Healthcare, Inc. is currently overvalued...."
      },
      {
        "title": "Prestige Consumer Healthcare Hits New 52-Week Low at $60.15",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/prestige-consumer-healthcare-hits-new-52-week-low-at-6015-3620105",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/PrestigeConsume_priceRelatedfactors_3620105.png",
        "date": "2025-10-14 18:46:03",
        "description": "Prestige Consumer Healthcare, Inc. has reached a new 52-week low, reflecting a notable decline in its performance over the past year. The company, with a market capitalization of USD 3,511 million, has struggled with modest growth and reported its lowest quarterly net sales and operating profit levels."
      },
      {
        "title": "Prestige Consumer Healthcare Stock Hits New 52-Week Low at $61.29",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/prestige-consumer-healthcare-stock-hits-new-52-week-low-at-6129-3586021",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/PrestigeConsume_priceRelatedfactors_3586021.png",
        "date": "2025-10-01 16:35:39",
        "description": "Prestige Consumer Healthcare, Inc. has reached a new 52-week low, trading at USD 61.29 as of September 30, 2025. The company has seen a 5.01% decline over the past year, with stagnant net sales and operating profit. Its market capitalization stands at USD 3,511 million, with a P/E ratio of 20.00."
      }
    ],
    "total": 16,
    "sid": "1159347",
    "stock_news_url": "https://www.marketsmojo.com/news/prestige-consumer-healthcare-inc-1159347"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Prestige Consumer Healthcare, Inc. Experiences Revision in Its Stock Evaluation Amid Market Dynamics

2025-11-10 15:55:39

Prestige Consumer Healthcare, Inc. has adjusted its valuation amid shifts in financial metrics and market standing within the Pharmaceuticals & Biotechnology sector. The company displays various profitability ratios and has faced performance challenges this year, contrasting with the broader market and highlighting the competitive landscape and differing risk profiles among peers.

Prestige Consumer Healthcare Stock Hits New 52-Week Low at $59.62

2025-11-03 17:06:31

Prestige Consumer Healthcare, Inc. has reached a new 52-week low, trading at USD 59.62 as of October 31, 2025. The company has seen a 7.75% decline over the past year, contrasting with the S&P 500's performance. Financial metrics show mixed results, with high institutional ownership and recent low quarterly sales figures.

Prestige Consumer Healthcare, Inc. Experiences Revision in Its Stock Evaluation Amid Competitive Landscape

2025-11-03 15:53:10

Prestige Consumer Healthcare, Inc. has adjusted its valuation, showcasing a P/E ratio of 20 and a price-to-book value of 2.48. The company demonstrates solid profitability with a ROCE of 12.76% and ROE of 12.16%, positioning it competitively within the pharmaceuticals and biotechnology sector.

Prestige Consumer Healthcare, Inc. Experiences Revision in Its Stock Evaluation Metrics

2025-10-27 15:53:58

Prestige Consumer Healthcare, Inc. has adjusted its valuation within the pharmaceuticals and biotechnology sector, with key metrics indicating operational efficiency and profitability. The company's performance has fluctuated, showing a decline over the past year compared to the broader market, highlighting challenges in the current environment.

Is Prestige Consumer Healthcare, Inc. overvalued or undervalued?

2025-10-21 12:07:26

As of 17 October 2025, the valuation grade for Prestige Consumer Healthcare, Inc. has moved from very attractive to attractive, indicating a shift towards a more cautious outlook. The company appears to be overvalued based on its current metrics, with a P/E ratio of 20, a Price to Book Value of 2.48, and an EV to EBITDA ratio of 14.39, all of which are higher than those of its peers. For instance, Alkermes Plc has a P/E of 13.77 and an EV to EBITDA of 9.41, suggesting that Prestige is trading at a premium compared to its industry counterparts. The company's recent performance shows a stark contrast to the broader market, with a year-to-date return of -20.49% compared to the S&P 500's gain of 13.30%. This underperformance, along with the high valuation ratios, reinforces the conclusion that Prestige Consumer Healthcare, Inc. is currently overvalued....

Is Prestige Consumer Healthcare, Inc. overvalued or undervalued?

2025-10-20 12:24:50

As of 17 October 2025, the valuation grade for Prestige Consumer Healthcare, Inc. has moved from very attractive to attractive, indicating a slight decline in perceived value. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 20, which is higher than the peer average of approximately 15.85, and a PEG ratio of 3.01, suggesting that the stock is expensive relative to its growth prospects. Additionally, the EV to EBITDA ratio stands at 14.39, which is also above the peer average of 11.55. In comparison to its peers, Alkermes Plc has a P/E ratio of 13.77 and an EV to EBITDA of 9.41, while ACADIA Pharmaceuticals, Inc. shows a higher P/E ratio of 19.28 but a significantly high EV to EBITDA of 33.99. This highlights that Prestige Consumer Healthcare is trading at a premium compared to some of its peers. Furthermore, the company's stock has underperformed relative ...

Is Prestige Consumer Healthcare, Inc. overvalued or undervalued?

2025-10-19 12:02:24

As of 17 October 2025, the valuation grade for Prestige Consumer Healthcare, Inc. moved from very attractive to attractive, indicating a shift in perceived value. The company appears overvalued based on its current metrics, with a P/E ratio of 20, a Price to Book Value of 2.48, and an EV to EBITDA of 14.39. In comparison, peers such as Alkermes Plc have a P/E of 13.77 and an EV to EBITDA of 9.41, suggesting that Prestige is trading at a premium relative to its industry. The stock has underperformed against the S&P 500 over various periods, notably with a year-to-date return of -20.49% compared to the index's 13.30%. This underperformance, alongside the elevated valuation ratios, reinforces the conclusion that Prestige Consumer Healthcare, Inc. is currently overvalued....

Prestige Consumer Healthcare Hits New 52-Week Low at $60.15

2025-10-14 18:46:03

Prestige Consumer Healthcare, Inc. has reached a new 52-week low, reflecting a notable decline in its performance over the past year. The company, with a market capitalization of USD 3,511 million, has struggled with modest growth and reported its lowest quarterly net sales and operating profit levels.

Prestige Consumer Healthcare Stock Hits New 52-Week Low at $61.29

2025-10-01 16:35:39

Prestige Consumer Healthcare, Inc. has reached a new 52-week low, trading at USD 61.29 as of September 30, 2025. The company has seen a 5.01% decline over the past year, with stagnant net sales and operating profit. Its market capitalization stands at USD 3,511 million, with a P/E ratio of 20.00.

View All News